PUMA BIOTECHNOLOGY, INC. Proceeds from Issuance of Debt
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Proceeds from Issuance of Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2024-02-29
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for the quarter ending 2022-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for the quarter ending 2021-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for the quarter ending 2020-12-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for the quarter ending 2020-09-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for fiscal 2023 was $0.00.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for fiscal 2021 was $98.50M, a 1066.51% increase from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. proceeds from issuance of debt for fiscal 2020 was $8.44M, a 66.22% decline from fiscal 2019.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $98.50M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $98.50M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $8.44M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.44M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $8.44M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $25.00M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $25.00M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $25.00M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $105.00M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |